PAOG "SCREAMS" BUY - CBD Pharmaceutical Prospect And Cannabis Legalization Prospects
January 7, 2021 -- InvestorsHub NewsWire -- via pennymillions
-- Amercian Bulls (americanbulls.com/PAOG) rated PAOG Group, Inc.
PAOG) a 'SCREAMING" BUY today:
"The green light
is on and this security is now
screaming BUY. It is action
time! The bullish pattern that was previously identified is finally
confirmed and a BUY signal is
generated. Most probably, it is the right time to participate in
bullish fervor. Do not miss this bullish opportunity."
PAOG announced a CRO contract with Veristat earlier this
week to develop a CBD Pharmaceutical Treamtent for
"PAOG today [Tuesday, Jan 5th] announced an engagement with
Veristat, Inc., a contract research organization headquartered in
Southborough, Massachusetts. PAOG has engaged Veristat to assist in
advancing PAOG with its proprietary Cannabidiol (CBD) extract for
the treatment of Chronic Obstructive Pulmonary Disorder (COPD)
toward initiating an Investigational New Drug application (IND)
with the Food and Drug Administration (FDA)."
'On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc.
(OTC Pink: KALY) RespRx is a cannabis treatment under development
for COPD derived from a patented cannabis extraction method - U.S.
Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
"Coupled with Joe Biden’s presidential win, the new
situation on Capitol Hill means that federal cannabis policy change
is in the cards for the 117th Congress."
This is a quoute from an article addressing the Democratic
Party Senate Win. See the rest of the article to get an idea
of legalization opportunities for cannabis:
Source - https://www.pennymillions.com/
Other stocks on the move - BLSP,